×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in ...
GlobeNewswire
ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to...
9 hours ago
The future of cancer immunotherapy with Elicio Therapeutics
Drug Target Review
In this exclusive interview with Dr Christopher Haqq, Executive Vice President, Head of Research and Development, and Chief Medical Officer...
2 months ago
Hitchhiking cancer vaccine makes progress in the clinic
MIT News
Elicio Therapeutics is testing a pancreatic cancer vaccine using technology first developed at MIT in clinical trials, with promising Phase...
3 months ago
Retail investors who hold 45% of Elicio Therapeutics, Inc. (NASDAQ:ELTX) gained 14%, insiders profited as well
Simply Wall Street
Elicio Therapeutics is not owned by hedge funds. With a 25% stake, CEO Robert Connelly is the largest shareholder. Yekaterina Chudnovsky is the...
1 month ago
Elicio initiates Phase II pancreatic cancer vaccine trial
Clinical Trials Arena
Elicio Therapeutics has initiated the Phase II trial of its cancer vaccine, ELI-002 7P, designed to treat pancreatic ductal adenocarcinoma.
4 months ago
Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in ...
GlobeNewswire
BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage...
1 month ago
Why Is Elicio Therapeutics (ELTX) Stock Up 11% Today?
InvestorPlace
Elicio Therapeutics stock is up with heavy trading of ELTX shares are posting positive preliminary results from a Phase 1 clinical trial.
4 months ago
Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry - Elicio Therapeu
Benzinga
Founded in 2011, Elicio Therapeutics Inc. ELTX+1.22%. + Free Alerts. has made several significant strides in the last 13 years.
1 month ago
Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR ...
Yahoo Finance
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage...
2 months ago
Elicio’s vaccine shows promise as potential cancer treatment in phase 1 trial
PharmaTimes
Results showed robust responses in patients with pancreatic and colorectal cancer. Elicio Therapeutics has announced positive phase 1...
3 months ago